Gastroenterology
Page 1 • 2 itemsGlobal pharma market insights for gastroenterology: track drug development, regulatory approvals, and M&A for IBD, liver disease, and GI oncology.
EnteroBiotix Raises £19M to Launch Phase 2b Microbiome Trial for Irritable Bowel Syndrome Treatment
EnteroBiotix secures £19M funding to initiate the largest Phase 2b microbiome trial for IBS treatment, with patient dosing starting Q2 2026.
Implantica RefluxStop Device Shows Excellent Long-Term Safety in Landmark 602-Patient European Study
Implantica's RefluxStop acid reflux device demonstrates excellent long-term safety in largest real-world study of 602 patients across 22 European centers.